Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesArbutus Biopharma Corp

Arbutus Biopharma Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.655 USD 0.00(0%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1715577
Market Cap
1002.42M
P/E
6.41

Momentum Score

…

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.62
Low
3.75
High
52 Week Price Range
3.50
Low
5.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Arbutus Biopharma is a clinical-stage biotechnology company developing therapies aimed at achieving a functional cure for chronic hepatitis B using small-molecule and RNA-based approaches. Long-term growth may be driven by positive clinical data, strategic collaborations, and regulatory approvals that could expand access to a large global HBV patient population. The company may appear positioned to benefit from advances in combination regimens that target both viral replication and host immune response.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.65
Dividend Yield
-
Revenue TTM
181.72M
Revenue Per Share
0.94
Gross Profit TTM
163.92M
Debt / Equity
0.05
ROE
89.58%
Net Debt
-13.82M
ROCE
-30.53%
Diluted EPS TTM
0.79

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -33.50M -69.92M -72.85M -65.01M -76.25M
Net income -33.50M -69.92M -72.85M -69.46M -77.35M
Selling general administrative 15.89M 22.11M 22.48M 17.83M 17.14M
Selling and marketing expenses - - 1.40M - -
Gross profit 13.72M 6.17M 18.14M 39.02M 10.99M
Reconciled depreciation 0.36M 1.38M 1.35M 1.43M 1.75M
Ebit -27.05M -69.78M -72.39M -65.46M -73.52M
Ebitda -26.69M -68.40M -70.99M -61.03M -71.52M
Depreciation and amortization 0.36M 1.38M 1.40M 4.42M 2.00M
Non operating income net other - - - 2.17M 0.13M
Operating income -27.05M -76.32M -78.10M -65.46M -73.52M
Other operating expenses 41.13M 82.49M 96.24M 102.24M 82.64M
Interest expense 0.10M 0.14M 0.46M 1.73M 2.86M
Tax provision - 0.00M 0.00M 4.44M -
Interest income 4.07M 6.58M 5.17M 2.19M 0.13M
Net interest income 3.97M 6.45M 4.44M 0.47M -2.73M
Income tax expense - - -0.00M 4.44M 1.10M
Total revenue 14.08M 6.17M 18.14M 39.02M 10.99M
Total operating expenses 40.77M 82.49M 96.24M 102.24M 82.64M
Cost of revenue 0.36M 1.38M 73.70M - -
Total other income expense net -6.45M 6.40M 5.25M 0.44M -2.73M
Net income from continuing ops -33.50M -69.92M -75.47M -69.46M -76.25M
Net income applicable to common shares - - - -69.46M -88.39M
Preferred stock and other adjustments - - - - 12.14M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 94.62M 131.71M 144.40M 195.42M 204.49M
Other current assets 1.24M 2.28M 3.65M 2.87M 4.45M
Total liab 18.04M 34.34M 38.38M 58.57M 35.05M
Total stockholder equity 76.58M 97.37M 106.02M 136.85M 169.44M
Other current liab 4.29M 5.25M 7.05M 12.51M 0.03M
Common stock 1421.43M 1410.03M 1349.82M 1318.74M 1286.64M
Capital stock 1421.43M 1410.03M 1349.82M 1318.74M 1286.64M
Retained earnings -1380.07M -1346.57M -1276.65M -1203.80M -1134.35M
Other liab - - - 23.89M 21.59M
Other assets - - 0.00M 0.10M 0.06M
Cash 18.01M 36.33M 26.29M 30.78M 109.28M
Total current liabilities 6.01M 15.62M 22.49M 32.86M 11.22M
Current deferred revenue - 7.57M 11.79M 16.46M 7.64M
Net debt -13.82M -35.04M -17.56M -28.59M -106.67M
Short term debt 0.55M 0.48M 0.42M 0.37M 0.38M
Short long term debt total 4.19M 1.29M 8.72M 2.19M 2.61M
Other stockholder equity 83.32M 82.05M 81.27M 72.41M 65.48M
Property plant equipment - - - 5.07M 5.98M
Total current assets 94.46M 127.32M 132.03M 151.14M 160.66M
Long term investments - 0.00M 6.28M 37.36M 35.69M
Net tangible assets - - - 136.85M 169.44M
Short term investments 73.46M 86.29M 99.72M 116.14M 46.03M
Net receivables 1.75M 2.41M 2.38M 4.23M 5.34M
Inventory - - -1.78M -2.87M -4.45M
Accounts payable 1.17M 2.32M 3.22M 3.52M 3.17M
Accumulated other comprehensive income -48.10M -48.13M -48.42M -50.49M -48.34M
Common stock total equity - - - 1318.74M 1286.64M
Retained earnings total equity - - - -1203.80M -1134.35M
Non currrent assets other 0.13M 0.03M - 0.10M 0.06M
Non current assets total 0.16M 4.39M 12.37M 44.28M 43.82M
Capital lease obligations 0.75M 1.29M 1.77M 2.19M 2.61M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 15.22M 22.95M 41.23M -74.43M -11.87M
Change to liabilities - - - 27.27M 1.54M
Total cashflows from investing activities 15.58M 22.95M 50.77M -74.94M -12.68M
Total cash from financing activities 5.72M 52.00M 30.65M 31.81M 137.24M
Change to operating activities - - - 2.02M 0.93M
Net income -33.50M -69.92M -72.85M -69.46M -76.25M
Change in cash -18.32M 10.04M -4.49M -78.51M 57.03M
Begin period cash flow 36.33M 26.29M 30.78M 109.28M 52.25M
End period cash flow 18.01M 36.33M 26.29M 30.78M 109.28M
Total cash from operating activities -39.64M -64.85M -85.94M -35.36M -67.53M
Issuance of capital stock 0.00M 44.12M 26.11M 20.32M 134.66M
Depreciation 0.36M 1.38M 1.40M 1.43M 1.75M
Other cashflows from investing activities -152.56M 164.64M 0.02M - -12.68M
Dividends paid - - - - -12.14M
Change to inventory - - 6.18M - -1.91M
Change to account receivables 1.38M -0.63M -0.42M -0.45M 0.41M
Sale purchase of stock - - - 10.97M 137.24M
Other cashflows from financing activities 5.72M 7.87M 0.80M -10.46M 14.71M
Change to netincome - - - 1.76M 2.18M
Capital expenditures 0.00M 0.18M 1.01M 0.51M 0.81M
Change receivables - - - -0.45M 0.41M
Cash flows other operating - - - 4.15M 1.82M
Cash and cash equivalents changes - - - -78.48M 57.03M
Change in working capital -10.02M -2.83M -18.23M 29.24M 0.93M
Stock based compensation 6.95M 8.99M 9.30M 7.18M 6.42M
Other non cash items -3.43M -2.47M -5.56M -3.75M 7.79M
Free cash flow -39.64M -65.03M -86.94M -35.87M -68.34M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ABUS
Arbutus Biopharma Corp		 -
-%		 3.65 6.41 10.25 5.52 3.92 5.07 6.02
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

701 Veterans Circle, Warminster, PA, United States, 18974

267 469 0914

https://www.arbutusbio.com

19

Name Title Year Born
Mr. William H. Collier Pres, CEO & Director 1960
Mr. David C. Hastings CPA CFO & Chief Accounting Officer 1961
Dr. Michael J. Sofia Ph.D. Chief Scientific Officer 1958
Mr. Michael J. McElhaugh COO & Chief Bus. Officer 1974
Ms. Lisa M. Caperelli VP of Investor Relations NA
Dr. Elizabeth Howard Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec. 1954
Dr. Gaston Picchio Ph.D. Chief Devel. Officer 1963
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C. Sec. 1951
Mr. Michael J. McElhaugh Co-Founder, Interim President, CEO & Director 1975
Ms. Lisa M. Caperelli Vice President of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…